Hi Anne,
When the UK was in the EU, regulatory approval was done by the European Medicines Agency (EMA): ironically, it was based in the UK.
Post Brexit, the UK set up its own regulator, the Medicines and Healthcare products Regulatory Agency (MHRA).
This paper indicates that the MHRA fell behind the EMA in approvals in 2021:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9797847/
Note that Abecma, one of the drugs mentioned, is a CAR-T treatment for myeloma.
Medical charities, including Myeloma UK, did ask the UK government to use the EMA for UK regulatory approval before Brexit actually happened. Didn’t happen.
Regards
Rabbit
